Home
Investment
Top Stories
Foreign Markets
Asia: Nikkei rises 1.1%
Mon, 01 Dec, 2008
INVESTMENT NEWS
Company Search
Search QCK.COM
Investment Home
News & Views
Top Stories
Charting
Company Search
Watchlist
Press Round Up
Press Tips
Broker Tips
Director Dealings
Stocks to Watch
Hot / Cold Sectors
Week Ahead
Foreign Markets
Asia: Nikkei rises 1.1%
Wed, 15 Oct 2008, 06:43:00
Concern about the deteriorating outlook for company profit initially took the Nikkei lower Wednesday but the index recovered later in the session as fears subsided and drug makers led gains.
The benchmark Nikkei 225 index closed up 99 points at 9,547, after falling nearly 2% earlier in the session. Yesterday the Nikkei soared 14%.
Drug makers like
Takeda Pharmaceutical
took the lead, rising over 6% as traders sought out defensive stocks.
Eisai Co
rose 4.7% and
Astellas Pharma
advanced 3%.
As the euphoria of Tuesday's session faded, traders focused on economic weakness and the earnings outlook for heavyweights such as
Toyota
. Shares in the carmaker tumbled nearly 5% on concern about declining sales in the US, its key export market.
Honda
dropped 6%.
Concern about a global slowdown also weighed on
Sony
and
Canon
.
Steel makers endured a difficult session as commodity prices headed lower. Shares in
Nippon Steel
and
JFE Holdings
both lost out.
Shipping stocks also came in for a rough ride as freight rates continued to fall.
Mitsui OSK Lines
was down over 10%,
Nippon Yusen
lost over 8% while
Kawasaki Kisen Kaisha
fell nearly 9%.
The Hang Seng remained firmly in the red Wednesday as financials came under the hammer.
Hong Kong's Hang Seng closed down 834 points at 15,998.
Hong Kong's
China Construction Bank
fell over 5% after Citigroup warned that profit for Chinese lenders could fall as more loans default in 2009.
ICBC
fell 2% while
Bank of Communications
lost over 4%.
Bank of East Asia
bucked the trend however following the government announcement that it will guarantee bank deposits.
©2004-2006 QCK.com
Tax Guides
|
Top 10 Tips
|
Financial News
|
Sitemap
|
Terms
|
About us
|
Contact